Basic Information
RNALocate ID: | RLID:11001788 |
RNA Symbol: | hsa-miR-142-3p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-142-3p |
RNA ID: | miRBase:MIMAT0000434 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 22211110 |
Tissue/Cell Line: | Breast milk |
Method: | Next-generation RNA sequencing |
The expression profile of selected miRNAs in breast milk exosomes. Originally published in Int J Biol Sci. Zhou Q, et al, 2012. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | Distribution and characterization of miRNAs in breast milk exosomes. (A) Distribution of pre-miRNAs. Out of 1,424 pre-miRNAs deposited in miRBase 17.0 (blue circle), 87 (6.11%) pre-miRNAs have been designated as immune-related pre-miRNAs based on annotation in the Pathway Central database (SABiosciences, MD, USA). Immune-related pre-miRNAs (59 of 452, 13.05%) are enriched in breast milk exosomes (red circle). χ2 test: Number of immune-related miRNAs and others detected in breast milk exosomes compared with the total entries in miRBase 17.0. (B) Top ten most highly expressed unique miRNAs. Plot of the unique miRNAs (starting from the miRNA with the highest counts, x-axis) versus their cumulative % of the total counts from 602 unique miRNAs detected in breast milk exosomes for each small RNA library. Values are means ± s.d. The dashed horizontal line at 62.3% represents the level of the top ten unique miRNAs and the % of individual miRNAs is marked by the gray line. (C-E) The expression profile of selected miRNAs in breast milk exosomes. (C) 59 immune-related pre-miRNAs; (D) miR-17-92 cluster and paralogous clusters, and (E) ten well-characterized tissue-specific pre-miRNAs. Data are collected from Figure 2. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001786 | Endoplasmic reticulum membrane | Cortical tissue | 32451872 |
RLID:11001787 | Exosome | B cell line (Raji)|Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11001789 | Exosome | Serum | 22427800 |
RLID:11001790 | Exosome | Brain tissue | 23382797 |
RLID:11001791 | Exosome | Plasma | 23663360 |
RLID:11001792 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11001794 | Microvesicle | Plasma | 19951903 |
RLID:11001795 | Microvesicle | Liver resident stem cells | 20668554 |
RLID:11001796 | Microvesicle | Hepatoma cells | 23771658 |
RLID-D:11000084 | Exosome | B lymphoblastoid cells|Chronic lymphocytic leukemia cells|Lymphoma tissue|Mast cells | |
RLID-D:11000362 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-142-3p | Mantle cell lymphoma | MNDR-E-MI-13915 |
MNDR | hsa-miR-142-3p | Splenic marginal zone lymphoma | MNDR-E-MI-13916 |
MNDR | hsa-miR-142-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-13917 |
MNDR | hsa-miR-142-3p | Oral squamous cell carcinoma | MNDR-E-MI-13918 |
MNDR | hsa-miR-142-3p | Medulloblastoma | MNDR-E-MI-13919 |
MNDR | hsa-miR-142-3p | B cell lymphoma of malt type | MNDR-E-MI-13920 |
MNDR | hsa-miR-142-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-13921 |
MNDR | hsa-miR-142-3p | Lymphoma | MNDR-E-MI-13922 |
MNDR | hsa-miR-142-3p | Lymphoma non-hodgkin | MNDR-E-MI-13923 |
MNDR | hsa-miR-142-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-13924 |
MNDR | hsa-miR-142-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-13925 |
MNDR | hsa-miR-142-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-13926 |
MNDR | hsa-miR-142-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-13927 |
MNDR | hsa-miR-142-3p | Her2-receptor positive breast cancer | MNDR-E-MI-13928 |
MNDR | hsa-miR-142-3p | Breast cancer luminal | MNDR-E-MI-13929 |
MNDR | hsa-miR-142-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-13930 |
MNDR | hsa-miR-142-3p | Dermatomyositis | MNDR-E-MI-13931 |
MNDR | hsa-miR-142-3p | Prostate cancer | MNDR-E-MI-13932 |
MNDR | hsa-miR-142-3p | Hirschsprung disease | MNDR-E-MI-13933 |
MNDR | hsa-miR-142-3p | Gastric cancer | MNDR-E-MI-13934 |
MNDR | hsa-miR-142-3p | Pre-eclampsia | MNDR-E-MI-13935 |
MNDR | hsa-miR-142-3p | Alzheimer disease | MNDR-E-MI-13936 |
MNDR | hsa-miR-142-3p | Sarcoma | MNDR-E-MI-13937 |
MNDR | hsa-miR-142-3p | Dysautonomia familial | MNDR-E-MI-13938 |
MNDR | hsa-miR-142-3p | Leukemia | MNDR-E-MI-13939 |
MNDR | hsa-miR-142-3p | Huntington disease | MNDR-E-MI-13940 |
MNDR | hsa-miR-142-3p | Chorea | MNDR-E-MI-13941 |
MNDR | hsa-miR-142-3p | Cardiovascular disease | MNDR-E-MI-13942 |
MNDR | hsa-miR-142-3p | Moyamoya disease | MNDR-E-MI-13943 |
MNDR | hsa-miR-142-3p | Lung cancer | MNDR-E-MI-13944 |
MNDR | hsa-miR-142-3p | Down syndrome | MNDR-E-MI-13945 |
MNDR | hsa-miR-142-3p | Parkinson disease | MNDR-E-MI-13946 |
MNDR | hsa-miR-142-3p | Basal-like breast cancer | MNDR-E-MI-13947 |
MNDR | hsa-miR-142-3p | Thyroid cancer | MNDR-E-MI-13948 |
MNDR | hsa-miR-142-3p | Pituitary neoplasms | MNDR-E-MI-13949 |
MNDR | hsa-miR-142-3p | Pancreatic cancer | MNDR-E-MI-13950 |
MNDR | hsa-miR-142-3p | Melanoma | MNDR-E-MI-13951 |
MNDR | hsa-miR-142-3p | Rectum adenocarcinoma | MNDR-E-MI-13952 |
MNDR | hsa-miR-142-3p | Colon cancer | MNDR-E-MI-13953 |
MNDR | hsa-miR-142-3p | Ischemic attack transient | MNDR-E-MI-13954 |
MNDR | hsa-miR-142-3p | Colon adenocarcinoma | MNDR-E-MI-13955 |
MNDR | hsa-miR-142-3p | Multiple sclerosis | MNDR-E-MI-13956 |
MNDR | hsa-miR-142-3p | Relapsing-remitting multiple sclerosis | MNDR-E-MI-13957 |
MNDR | hsa-miR-142-3p | Familial ovarian cancer | MNDR-E-MI-13958 |
MNDR | hsa-miR-142-3p | Asthma | MNDR-E-MI-13959 |
MNDR | hsa-miR-142-3p | Endometriosis | MNDR-E-MI-13960 |
MNDR | hsa-miR-142-3p | Carcinoma ductal breast | MNDR-E-MI-13961 |
MNDR | hsa-miR-142-3p | Glioblastoma | MNDR-E-MI-13962 |
MNDR | hsa-miR-142-3p | Astrocytoma | MNDR-E-MI-13963 |
MNDR | hsa-miR-142-3p | Malignant glioma | MNDR-E-MI-13964 |
MNDR | hsa-miR-142-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-13965 |
MNDR | hsa-miR-142-3p | Osteosarcoma | MNDR-E-MI-13966 |
MNDR | hsa-miR-142-3p | Liposarcoma | MNDR-E-MI-13967 |
MNDR | hsa-miR-142-3p | Breast carcinoma | MNDR-E-MI-13968 |
MNDR | hsa-miR-142-3p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-13969 |
MNDR | hsa-miR-142-3p | Meningioma | MNDR-E-MI-13970 |
MNDR | hsa-miR-142-3p | Uterine cancer | MNDR-E-MI-13971 |
MNDR | hsa-miR-142-3p | Gastric adenocarcinoma | MNDR-E-MI-13972 |
MNDR | hsa-miR-142-3p | Cervical squamous cell carcinoma | MNDR-E-MI-13973 |
MNDR | hsa-miR-142-3p | Pituitary adenoma | MNDR-E-MI-13974 |
MNDR | hsa-miR-142-3p | Lung squamous cell carcinoma | MNDR-E-MI-13975 |
MNDR | hsa-miR-142-3p | Carcinoma lung non-small-cell | MNDR-E-MI-13976 |
MNDR | hsa-miR-142-3p | Lung adenocarcinoma | MNDR-E-MI-13977 |
MNDR | hsa-miR-142-3p | Thyroid carcinoma | MNDR-E-MI-13978 |
MNDR | hsa-miR-142-3p | Bladder urothelial carcinoma | MNDR-E-MI-13979 |
MNDR | hsa-miR-142-3p | Pancreatic adenocarcinoma | MNDR-E-MI-13980 |
MNDR | hsa-miR-142-3p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-13981 |
MNDR | hsa-miR-142-3p | Carcinoma renal cell | MNDR-E-MI-13982 |
MNDR | hsa-miR-142-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-13983 |
MNDR | hsa-miR-142-3p | Clear cell renal cell carcinoma | MNDR-E-MI-13984 |
MNDR | hsa-miR-142-3p | Cholangiocarcinoma | MNDR-E-MI-13985 |
MNDR | hsa-miR-142-3p | Prolactinoma | MNDR-E-MI-13986 |
MNDR | hsa-miR-142-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-13987 |
MNDR | hsa-miR-142-3p | Testicular germ cell cancer | MNDR-E-MI-13988 |
MNDR | hsa-miR-142-3p | Kidney diseases | MNDR-E-MI-13989 |
MNDR | hsa-miR-142-3p | T-cell acute lymphoblastic leukemia | MNDR-E-MI-13990 |
MNDR | hsa-miR-142-3p | Fibromyalgia | MNDR-E-MI-13991 |
MNDR | hsa-miR-142-3p | Breast invasive carcinoma | MNDR-E-MI-13992 |
MNDR | hsa-miR-142-3p | Hepatocellular carcinoma | MNDR-E-MI-13993 |
MNDR | hsa-miR-142-3p | Embryonal cancer | MNDR-E-MI-13994 |
MNDR | hsa-miR-142-3p | Familiar ovarian carcinoma | MNDR-E-MI-13995 |
MNDR | hsa-miR-142-3p | B-cell lymphoma | MNDR-E-MI-13996 |
MNDR | hsa-miR-142-3p | Rheumatoid arthritis | MNDR-E-MI-13997 |
MNDR | hsa-miR-142-3p | Osteoarthritis | MNDR-E-MI-13998 |
MNDR | hsa-miR-142-3p | Hodgkin lymphoma | MNDR-E-MI-13999 |
MNDR | hsa-miR-142-3p | Ulcerative colitis | MNDR-E-MI-14000 |
MNDR | hsa-miR-142-3p | Burkitt lymphoma | MNDR-E-MI-14001 |
MNDR | hsa-miR-142-3p | Tonsil cancer | MNDR-E-MI-14002 |
MNDR | hsa-miR-142-3p | Neuromyelitis optica | MNDR-E-MI-14003 |
MNDR | hsa-miR-142-3p | Psoriasis | MNDR-E-MI-14004 |
MNDR | hsa-miR-142-3p | Skin cutaneous melanoma | MNDR-E-MI-14005 |
MNDR | hsa-miR-142-3p | Skin melanoma | MNDR-E-MI-14006 |
MNDR | hsa-miR-142-3p | Acute myeloid leukemia | MNDR-E-MI-14007 |
MNDR | hsa-miR-142-3p | Colorectal cancer | MNDR-E-MI-14008 |
MNDR | hsa-miR-142-3p | Nasopharyngeal carcinoma | MNDR-E-MI-14009 |
MNDR | hsa-miR-142-3p | Nasopharynx carcinoma | MNDR-E-MI-14010 |
MNDR | hsa-miR-142-3p | Multiple myeloma | MNDR-E-MI-14011 |
MNDR | hsa-miR-142-3p | Acute lymphoblastic leukemia | MNDR-E-MI-14012 |
MNDR | hsa-miR-142-3p | Ependymoma | MNDR-E-MI-14013 |
MNDR | hsa-miR-142-3p | Nasopharyngeal cancer | MNDR-E-MI-14014 |
MNDR | hsa-miR-142-3p | Prostatic neoplasms | MNDR-E-MI-14015 |
MNDR | hsa-miR-142-3p | Aids dementia complex | MNDR-E-MI-14016 |
MNDR | hsa-miR-142-3p | Cerebral hemorrhage traumatic | MNDR-E-MI-14017 |
MNDR | hsa-miR-142-3p | Intracranial hemorrhage hypertensive | MNDR-E-MI-14018 |
MNDR | hsa-miR-142-3p | Stroke lacunar | MNDR-E-MI-14019 |
MNDR | hsa-miR-142-3p | Breast cancer her3+ negative | MNDR-E-MI-14020 |
MNDR | hsa-miR-142-3p | Multiple sclerosis susceptibility | MNDR-E-MI-14021 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCG2 | Homo sapiens | RR00024737 |
TOP